Simulated population data suggests that the lifetime risk of cervical cancer is lower for women who stop screening after a negative DNA test for oncogenic HPV.
At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.
The test is intended to identify patients with ROS1, NTRK, and ALK gene fusions for treatment with TP's investigational drug repotrectinib.
The two companies have signed a collaboration agreement to provide Promega's microsatellite instability testing technology for immuno-oncology.
The firm’s two-step multiplexed-tandem PCR tool identifies low concentrations of multiple STI pathogens in samples with high concentrations of other pathogens in three hours.
The plaintiffs claim that Qiagen's QIAseq kits infringe Archer's US Patent No. 10,017,810, which covers parts of its Anchored Multiplex PCR (AMP) technology.
Collaborators said that the test is accurate and reliable for the rapid detection of the most common gram-positive bacteria responsible for bloodstream infections.
The new assay simultaneously detects four viral targets in donated blood plasma in a single sample and can add value to the biologics development space.
The funding will help Mobidiag scale up production of its Novodiag instruments and disposable cartridges, and improve its global sales and marketing activities.
The blood-based test could eventually become a rapid point-of-care diagnostic in the ICU, with startup Microbiome as a commercial vehicle.
Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.
The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.
The New York Times writes that natural history museums are helping round out genetic studies with older specimens.
In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.